CDXC Stock Overview
ChromaDex Corporation operates as a bioscience company focusing on healthy aging.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.92|
|52 Week High||US$10.78|
|52 Week Low||US$1.51|
|1 Month Change||9.71%|
|3 Month Change||-18.99%|
|1 Year Change||-79.04%|
|3 Year Change||-58.71%|
|5 Year Change||-49.74%|
|Change since IPO||-82.93%|
Recent News & Updates
|CDXC||US Life Sciences||US Market|
Return vs Industry: CDXC underperformed the US Life Sciences industry which returned -15.9% over the past year.
Return vs Market: CDXC underperformed the US Market which returned -18.4% over the past year.
|CDXC Average Weekly Movement||13.7%|
|Life Sciences Industry Average Movement||11.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CDXC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: CDXC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex Fundamentals Summary
|CDXC fundamental statistics|
Is CDXC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CDXC income statement (TTM)|
|Cost of Revenue||US$27.24m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.40|
|Net Profit Margin||-39.25%|
How did CDXC perform over the long term?See historical performance and comparison
Is CDXC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CDXC?
Other financial metrics that can be useful for relative valuation.
|What is CDXC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CDXC's PS Ratio compare to its peers?
|CDXC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: CDXC is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (8.9x).
Price to Earnings Ratio vs Industry
How does CDXC's PE Ratio compare vs other companies in the U.S. Life Sciences Industry?
Price-To-Sales vs Industry: CDXC is good value based on its Price-To-Sales Ratio (1.9x) compared to the US Life Sciences industry average (5.2x)
Price to Sales Ratio vs Fair Ratio
What is CDXC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.9x|
|Fair PS Ratio||4.6x|
Price-To-Sales vs Fair Ratio: CDXC is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).
Share Price vs Fair Value
What is the Fair Price of CDXC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CDXC ($1.92) is trading below our estimate of fair value ($18.29)
Significantly Below Fair Value: CDXC is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDXC's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is ChromaDex forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDXC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: CDXC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CDXC is expected to become profitable in the next 3 years.
Revenue vs Market: CDXC's revenue (22.5% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CDXC's revenue (22.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDXC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has ChromaDex performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDXC is currently unprofitable.
Growing Profit Margin: CDXC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDXC is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare CDXC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDXC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).
Return on Equity
High ROE: CDXC has a negative Return on Equity (-106.22%), as it is currently unprofitable.
Discover strong past performing companies
How is ChromaDex's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CDXC's short term assets ($44.5M) exceed its short term liabilities ($18.7M).
Long Term Liabilities: CDXC's short term assets ($44.5M) exceed its long term liabilities ($8.4M).
Debt to Equity History and Analysis
Debt Level: CDXC is debt free.
Reducing Debt: CDXC had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CDXC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CDXC has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 18.9% each year.
Discover healthy companies
What is ChromaDex current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDXC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDXC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CDXC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rob Fried (61 yo)
Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of ChromaDex Corp. since June 22, 2018 and its a Director since July 2015. Mr. Fried was the Chief Operating Officer of ChromaDe...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD1.10M) is above average for companies of similar size in the US market ($USD749.40K).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
Experienced Management: CDXC's management team is considered experienced (3.8 years average tenure).
Experienced Board: CDXC's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CDXC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ChromaDex Corporation's employee growth, exchange listings and data sources
- Name: ChromaDex Corporation
- Ticker: CDXC
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$131.554m
- Shares outstanding: 68.52m
- Website: https://www.chromadex.com
Number of Employees
- ChromaDex Corporation
- 10900 Wilshire Boulevard
- Suite 600
- Los Angeles
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.